Sera Prognostics, Inc. reported a net loss of $8.4 million for the first quarter of 2026, slightly higher than the $8.2 million loss recorded in the same period of 2025. Revenue for the quarter was $14,000, a significant decrease from $38,000 year-over-year. The company's operating expenses totaled $9.4 million, which is a marginal increase from $9.3 million in the previous year. The loss from operations was $9.4 million, compared to $9.3 million in the prior year, indicating a relatively stable operational performance despite the decline in revenue.
In terms of financial position, Sera's total assets decreased to $93.5 million as of March 31, 2026, down from $101.9 million at the end of 2025. The company reported cash and cash equivalents of $4.2 million, alongside marketable securities totaling $82.6 million. The accumulated deficit increased to $320.1 million, reflecting the ongoing challenges in achieving profitability. The company’s workforce was reduced by approximately 18% in May 2026, as part of a strategic shift to focus on the commercialization of its PreTRM test, which aims to predict preterm birth risk.
Sera's operational focus has shifted towards the commercialization of its PreTRM test, which is the only validated blood-based biomarker test for predicting preterm birth risk. The company has recently published findings from the PRIME study, which demonstrated significant reductions in neonatal morbidity and hospital stays for at-risk pregnancies. This study is expected to enhance the test's market acceptance and drive future revenue growth. The company is also working on expanding its commercial team and enhancing payer engagement to facilitate broader adoption of the PreTRM test.
Looking ahead, Sera Prognostics anticipates continued operating losses as it invests in the commercialization of the PreTRM test and other pipeline products. The company has projected a decrease in research and development expenses as it reallocates resources towards commercialization efforts. Sera expects that its existing cash and cash equivalents will be sufficient to fund operations through 2029, provided it can secure additional contracts with payers and health systems. However, the company acknowledges the risks associated with achieving significant revenue and may need to seek additional funding to support its operations and growth initiatives.
About SERA PROGNOSTICS, INC.
Sera Prognostics specializes in women’s health by developing blood-based biomarker tests and predictive analytics to improve pregnancy outcomes. Its core product, the PreTRM test, accurately predicts preterm birth risk, enabling proactive interventions. The company leverages proprietary proteomics, bioinformatics, and extensive biobanks to address unmet needs in maternal-fetal medicine, targeting healthcare providers, payers, and pregnant women worldwide.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.